Review findings

At present, there is no documented, reproducible clinical efficacy for ipamorelin in therapeutic indications based on the available evidence.

Evidence Gaps and Limitations # The current evidence base for Ipamorelin consists primarily of preclinical studies.

References # Related Reading # Ipamorelin research studies and evidence Ipamorelin dosing protocols Ipamorelin side effects profile CJC-1295 DAC research guide CJC-1295 without DAC research guide Stay current on Ipamorelin research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

Peptide Protocol Wiki June 4, 2026 Retatrutide BPC-157 Tesamorelin + 6 more Guide 12 min read Core Peptides Review 2026: COAs, Finnrick Controversy, and Whether the Score Holds Up An honest 2026 review of Core Peptides covering product range, payment flexibility, shipping, COA transparency, and how the Finnrick Analytics controversy should change how you read vendor ratings.

GI‑2 responder (composite of tolerating diet + first stool) Median time to first tolerated meal: 25.3 h (ipamorelin) vs 32.6 h (placebo);

2020 (review summary) Review of growth hormone secretagogues / clinical development Narrative review of GHS clinical trials including ipamorelin NA (review) Summarizes reported clinical endpoints across trials Notes ipamorelin did not shorten time to first meal vs placebo in the initial RCT and a subsequent Phase II showed no significant colonic function ...

IV dosing; enrolled ~117; completed Recovery of GI function until hospital discharge (per protocol) Protocol-level only; peer-reviewed publication corresponds to Beck 2014 Protocol lists safety monitoring; registry notes no DMC in record Modest sample size; industry sponsor; protocol-only registry information without independent full dataset in registry entry POI (registry) NCT01280344 (listed in reviews) Phase 2, randomized; n≈320 (registry record) Recovery of gastrointestinal function / GI endpoints (registry) Completed trial per registry but no detailed peer-reviewed results available in retrieved texts Not reported/published in retrieved sources Larger Phase 2 exists but lack of published results creates an evidence gap and potential reporting/publication bias GH secretion (pharmacodynamics) Ishida et al., review (2020) Review summarizing early-phase human PD and preclinical studies; small human PD assessments Pharmacodynamic measures: plasma GH peak timing and magnitude after dosing Ipamorelin produces a rapid GH peak in humans (~0.67 h post-dose) — demonstrating expected PD effect Human safety data limited in review; mainly short-term PD observations Evidence based

Restore access No thanks, continue reading Related Reading Peptide Sermorelin GHRH analog for growth hormone release Peptide CJC-1295 No DAC (Mod GRF 1-29) common stack partner Peptide GHRP-2 growth hormone releasing peptide How Ipamorelin works at the cellular level Overview of Ipamorelin benefits and applications Scientific Details Molecular Formula C38H49N9O5 Molecular Weight 711.85 Da CAS Number 170851-70-4 Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 What is Ipamorelin? # Ipamorelin is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

Restore access No thanks, continue reading Related Reading Peptide Sermorelin GHRH analog for growth hormone release Peptide CJC-1295 No DAC (Mod GRF 1-29) common stack partner Peptide GHRP-2 growth hormone releasing peptide How Ipamorelin works at the cellular level Overview of Ipamorelin benefits and applications Scientific Details Molecular Formula C38H49N9O5 Molecular Weight 711.85 Da CAS Number 170851-70-4 Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 What is Ipamorelin? # Ipamorelin is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

on surrogate biomarker (GH) not linked to clinical functional/long-term outcomes; limited controlled trials on clinical endpoints Body composition / hypogonadal males (class review) Sinha et al., review (2020) Narrative review of GHS (includes ipamorelin among agents) Reported endpoints across studies: lean mass, fat mass, appetite/strength (varied across agents) Reviews suggest class-level potential to improve body composition, but ipamorelin-specific RCT evidence is lacking (only limited human trials overall) Clinical safety data for ipamorelin sparse; class safety signals vary by agent Paucity of ipamorelin-specific human RCTs for body-composition or functional outcomes; much inference is from other GHS or preclinical data Comparative / regulatory context Reviews and POI literature noting approved agent alvimopan Review/clinical-context summaries N/A (regulatory/comparative context) No approved human indications identified for ipamorelin in reviewed sources; alvimopan is an approved agent shown to reduce POI duration Ipamorelin detectable in dried blood spots (analytical papers); lack of approval implies limited postmarketing safety data Absence of regulatory approval; limited published clinical evidence vs. approved comparator (alvimopan); detection/anti-doping considerations add n...

lacebo 58) tested IV ipamorelin 0.03 mg/kg twice daily after bowel resection.

ve reviews emphasize a paucity of ipamorelin‑specific human efficacy data for anti‑aging or performance outcomes.

Evidence gaps: No Phase 3 trials; no published peer‑reviewed outcomes from a larger completed Phase 2 (NCT01280344); absence of ipamorelin‑specific RCTs demonstrating improvements in body composition, sarcopenia, hypogonadism‑related outcomes, or athletic performance; lack of long‑term metabolic, cardiovascular, and endocrine safety data; limited PK/PD‑to‑clinical outcome bridging and dose‑ranging data in target populations.

wth hormone secretion for anti-aging, recovery, and body composition 💉 Dosing Amount 200-300 mcg per injection Frequency 1-3 times daily (commonly twice daily: morning and before bed) Duration 8-12 weeks, then 2-4 weeks off 💊 Administration Route SC Schedule 1-3 times daily (commonly twice daily: morning and before bed) Timing On empty stomach; morning fasted, post-workout, and/or 30-60 min before bed 📅 Cycle Duration 8-12 weeks, then 2-4 weeks off Rest Period 4 weeks off between cycles Repeatable Yes Preparation & Storage Diluent: Bacteriostatic water ⚗️ Suggested Bloodwork ( 6 tests) IGF-1 When: Baseline Why: Baseline growth hormone activity Fasting glucose and HbA1c When: Baseline Why: GH peptides can affect glucose metabolism CBC with differential When: Baseline Why: Baseline blood cell counts IGF-1 When: 4-6 weeks Why: Confirm GH elevation Fasting glucose When: 4 weeks Why: Monitor glucose handling IGF-1 When: Ongoing Why: Levels above age-adjusted reference range ⚠️ Levels above age-adjusted reference range 💡 Key Considerations → Best taken on empty stomach (2+ hours after eating) → No carbs/fats 30 min before or after injection → Often stacked with CJC-1295 DAC (weekly) or Mod GRF 1-29 (per injection) for synergistic GH release → Contraindication: Avoid in active cancer or pituitary disorders Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — fre

Report an Error Compare Ipamorelin with Other Peptides Ipamorelin vs GHRP-6 Ipamorelin is the preferred choice for most research contexts due to its exceptional selectivity — producing clean GH release without cortisol, prolactin, or appetite effects.

Based on 200 + community reports View community protocols Frequently Asked Questions About Ipamorelin What makes ipamorelin different from other GH peptides?

Can you stack ipamorelin with CJC-1295?

These peptides operate through complementary pathways (GHRH vs GHRP) and are frequently studied in combination for synergistic GH release greater than either alone. → Ipamorelin vs Tesamorelin Tesamorelin is the evidence-backed, FDA-approved choice for HIV-associated lipodystrophy;

7.8 /10 International Biotech Peptides 7.7 /10 US Domestic Eternal Peptides 7.7 /10 US Domestic Particle Peptides 7.7 /10 International Verified Peptides 7.6 /10 US Domestic From $ 53.00 View all 54 vendors → Explore Further Calculate Ipamorelin doses Pre-filled reconstitution and dose math for Ipamorelin New to peptides?

Learn the basics of peptide science and research Related Peptides View all peptides → Growth Hormone Anti-Aging & Longevity CJC-1295 DAC CJC-1295 DAC: Long-acting GHRH analog with extended half-life.

Ipamorelin: Selective GH Secretagogue Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Selectivity and functional outcomes Endocrine selectivity: Ipamorelin produces robust, selective GH pulses without significant ACTH/cortisol or prolactin elevations in preclinical and clinical contexts, differentiating it from some other GHSs and from ghrelin.

Ipamorelin’s selective endocrine profile for GH, together with its central and peripheral ghrelin-like actions, accounts for its effects on GH/IGF-1 physiology and gastrointestinal motility.

Therapeutic Applications # Objective: Provide a comprehensive, evidence-based summary of ipamorelin’s therapeutic applications and documented outcomes in preclinical and clinical research, with specific study results.

Peptide Protocol Wiki March 14, 2026 Tesamorelin Sermorelin Ipamorelin + 5 more You Might Also Like Related content you may find interesting Peptide Growth Hormone Sermorelin Peptide Growth Hormone GHRP-2 Peptide Growth Hormone GHRP-6 Peptide Growth Hormone Hexarelin Table of Contents What is Ipamorelin?

Peptide Protocol Wiki March 14, 2026 Tesamorelin Sermorelin Ipamorelin + 5 more You Might Also Like Related content you may find interesting Peptide Growth Hormone Sermorelin Peptide Growth Hormone GHRP-2 Peptide Growth Hormone GHRP-6 Peptide Growth Hormone Hexarelin Table of Contents What is Ipamorelin?

Peptide Protocol Wiki June 4, 2026 Retatrutide BPC-157 Tesamorelin + 6 more Guide 12 min read Core Peptides Review 2026: COAs, Finnrick Controversy, and Whether the Score Holds Up An honest 2026 review of Core Peptides covering product range, payment flexibility, shipping, COA transparency, and how the Finnrick Analytics controversy should change how you read vendor ratings.

ipamorelin did not increase plasma ACTH or cortisol in prior characterization cited by the authors.

Peptide Protocol Wiki March 30, 2026 BPC-157 Thymosin Alpha-1 AOD-9604 + 16 more Guide 9 min read Best Growth Hormone Peptides Ranked: 2026 Evidence-Based Guide A ranked comparison of 8 growth hormone secretagogues and related peptides — from FDA-approved tesamorelin to IGF-1 LR3 —

wth hormone secretion for anti-aging, recovery, and body composition 💉 Dosing Amount 200-300 mcg per injection Frequency 1-3 times daily (commonly twice daily: morning and before bed) Duration 8-12 weeks, then 2-4 weeks off 💊 Administration Route SC Schedule 1-3 times daily (commonly twice daily: morning and before bed) Timing On empty stomach; morning fasted, post-workout, and/or 30-60 min before bed 📅 Cycle Duration 8-12 weeks, then 2-4 weeks off Rest Period 4 weeks off between cycles Repeatable Yes Preparation & Storage Diluent: Bacteriostatic water ⚗️ Suggested Bloodwork ( 6 tests) IGF-1 When: Baseline Why: Baseline growth hormone activity Fasting glucose and HbA1c When: Baseline Why: GH peptides can affect glucose metabolism CBC with differential When: Baseline Why: Baseline blood cell counts IGF-1 When: 4-6 weeks Why: Confirm GH elevation Fasting glucose When: 4 weeks Why: Monitor glucose handling IGF-1 When: Ongoing Why: Levels above age-adjusted reference range ⚠️ Levels above age-adjusted reference range 💡 Key Considerations → Best taken on empty stomach (2+ hours after eating) → No carbs/fats 30 min before or after injection → Often stacked with CJC-1295 DAC (weekly) or Mod GRF 1-29 (per injection) for synergistic GH release → Contraindication: Avoid in active cancer or pituitary disorders Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — fre

dose: 300 mcg · cycle: Cycle · timing: morning · frequency: daily · reconstitution: Bacteriostatic

IV dosing in surgical patients 0.03 mg/kg twice daily IV (reported dosing) Time to first tolerated standardized meal;

dose: 0.03 mg · route: IV · frequency: twice daily

Ipamorelin 0.03 mg/kg IV twice daily did not significantly improve time to first tolerated meal vs placebo .

dose: 0.03 mg · route: IV · frequency: twice daily

Clinical outcomes Phase II proof-of-concept RCT in bowel resection patients (Beck 2014): Ipamorelin 0.03 mg/kg IV twice daily vs placebo.

dose: 0.03 mg · route: IV · frequency: twice daily

Proof‑of‑concept signals in laparotomy subgroup but primary endpoints not met; safety signals noted; further development questioned ClinicalTrials.gov NCT00672074 (Phase 2 registry; n=117) (NCT00672074, NCT00672074a) POI (post‑bowel resection) Phase 2, randomized, parallel, double‑blind, placebo‑controlled, multiple‑dose IV; quadruple‑masked IV multiple‑dose (trial record; publication reports 0.03 mg/kg BID in RCT) Recovery of GI function until hospital discharge (registry primary outcome) Trial completed (primary completion Dec 2009); results reported in derived publication (Beck 2014) (NCT00672074, NCT00672074a) Eligibility/exclusions aimed to mitigate safety risks (excl. significant liver disease, abnormal labs/EKG); registry lists no DMC (NCT00672074a) Phase 2 completed and reported; results available in peer‑reviewed RCT (NCT00672074) ClinicalTrials.gov NCT01280344 (Phase 2 registry; n=320) POI / recovery of GI function Phase 2, randomized IV vs placebo (registry entry) IV (registry) Recovery of GI function / GI endpoints (registry) Trial listed

dose: 0.03 mg · route: IV · frequency: BID

lacebo 58) tested IV ipamorelin 0.03 mg/kg twice daily after bowel resection.

dose: 0.03 mg · route: IV · frequency: twice daily

In clinical Phase II testing, ipamorelin 0.03 mg/kg IV BID did not significantly shorten time to first tolerated meal or consistently improve composite GI recovery endpoints, with a signal limited to an open laparotomy subgroup; safety showed common GI AEs, occasional hypokalemia, an

dose: 0.03 mg · route: IV · frequency: BID

Preclinical outcomes Rat POI model (laparotomy and intestinal manipulation): A single IV dose (1 mg/kg) significantly shortened colonic transit time vs vehicle; however, single dosing did not increase cumulative fecal output, food intake, or 48-h weight gain.

dose: 1 mg · route: IV

2009 (rat POI) Postoperative ileus (POI) Preclinical: laparotomy + intestinal manipulation in rats Single iv 0.01–1 mg/kg; repetitive iv 0.01–1 mg/kg (4 doses/day) Colonic transit time; cumulative fecal pellet output; food intake;

dose: 1 mg · route: iv

Repetitive IV dosing (0.1–1 mg/kg, four doses/day over 48 h) significantly increased cumulative fecal pellet output and food intake;

dose: 1 mg · route: IV

1 mg/kg increased 48-h body-weight gain.

dose: 1 mg

1 mg/kg increased 48-h weight...

dose: 1 mg

48-h body weight Single 1 mg/kg shortened colonic transit vs vehicle; repetitive 0.1 and 1 mg/kg increased fecal output & food intake;

dose: 1 mg

Peptide Directory All Peptides Metabolic Anti-Obesity Anti-Aging Immune Hormonal View All Categories Directory Peptide Vendors Analytics Labs Side Effects Database Report a Side Effect Learn Start Here What Are Peptides?

Ipamorelin: Selective GH Secretagogue Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About Ipamorelin 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides Ipamorelin Growth Hormone Anti-Aging & Longevity phase2 Ipamorelin Also known as: IPA, NNC 26-0161 Compare with 5 peptide s Research compiled by Peptide Protocol Wiki 📅 Updated February 1, 2026 Citations Verified TL;DR Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that selectively stimulates GH release via the ghrelin (GHS-R1a) receptor.

Browse all growth hormone peptides → Table of Contents 📌 TL;DR • Selective GH release with minimal cortisol and prolactin elevation • Dose-dependent GH secretion demonstrated in human studies • Favorable safety profile in Phase I/II clinical trials • Synergistic effects when combined with GHRH analogs like sermorelin Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Selective gro

Safety in the RCT: Ipamorelin was “well tolerated” overall; any treatment-emergent adverse event occurred in 87.5% with ipamorelin vs 94.8% with placebo.

Two fatal serious adverse events occurred in ipamorelin-treated patients and were considered possibly related to study drug.

Safety In the POI RCT, overall treatment‑emergent adverse events were common in both arms and typical of postoperative recovery; ipamorelin showed higher rates of hypokalemia, more frequent hyperglycemia shifts, and two fatal SAEs (postoperative anastomotic leaks) deemed possibly related; most SAEs occurred after therapy completion.

References # Related Reading # Ipamorelin research studies and evidence Ipamorelin dosing protocols Ipamorelin side effects profile CJC-1295 DAC research guide CJC-1295 without DAC research guide Stay current on Ipamorelin research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

Covers Drug Affinity Complex mechanism, GH/IGF-1 elevation, dosing, and side effects.

Covers pulsatile GH release, Ipamorelin stack synergy, dosing, and side effects.

Covers appetite effects, cardiac cytoprotection research, dosing, side effects, and GHRP-2 comparison. ⚠️ Medical Disclaimer This website is for educational and informational purposes only.

For standard GH optimization protocols, ipamorelin's clean hormonal profile makes it the more practical and better-tolerated option. → Ipamorelin vs GHRP-2 Ipamorelin for clean, selective GH release with minimal side effects;

ble research peptide for GH optimization protocols where regulatory approval is not required → Related Articles Guide 9 min read Best Peptides to Stack with Retatrutide (2026 Research Guide) A 2026 research-focused review of the peptides most often discussed alongside retatrutide for GI side effects, lean-mass preservation, hair and skin changes, sleep, and adjunct fat loss — what the literature does and does not support.

wth hormone secretion for anti-aging, recovery, and body composition 💉 Dosing Amount 200-300 mcg per injection Frequency 1-3 times daily (commonly twice daily: morning and before bed) Duration 8-12 weeks, then 2-4 weeks off 💊 Administration Route SC Schedule 1-3 times daily (commonly twice daily: morning and before bed) Timing On empty stomach; morning fasted, post-workout, and/or 30-60 min before bed 📅 Cycle Duration 8-12 weeks, then 2-4 weeks off Rest Period 4 weeks off between cycles Repeatable Yes Preparation & Storage Diluent: Bacteriostatic water ⚗️ Suggested Bloodwork ( 6 tests) IGF-1 When: Baseline Why: Baseline growth hormone activity Fasting glucose and HbA1c When: Baseline Why: GH peptides can affect glucose metabolism CBC with differential When: Baseline Why: Baseline blood cell counts IGF-1 When: 4-6 weeks Why: Confirm GH elevation Fasting glucose When: 4 weeks Why: Monitor glucose handling IGF-1 When: Ongoing Why: Levels above age-adjusted reference range ⚠️ Levels above age-adjusted reference range 💡 Key Considerations → Best taken on empty stomach (2+ hours after eating) → No carbs/fats 30 min before or after injection → Often stacked with CJC-1295 DAC (weekly) or Mod GRF 1-29 (per injection) for synergistic GH release → Contraindication: Avoid in active cancer or pituitary disorders Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — fre

A larger follow-up Phase II trial also failed to show significant improvements in GI function, and development for GI indications was discontinued.

elin group possibly related (anastomotic leaks) Phase 2-sized, underpowered for definitive efficacy; exploratory subgroup analyses; short follow-up; restrictive exclusions limit generalizability POI (registry/protocol) NCT00672074 (2008) (NCT00672074) Phase 2, randomized, double-blind, quadruple-masked;

IV dosing; enrolled ~117; completed Recovery of GI function until hospital discharge (per protocol) Protocol-level only; peer-reviewed publication corresponds to Beck 2014 Protocol lists safety monitoring; registry notes no DMC in record Modest sample size; industry sponsor; protocol-only registry information without independent full dataset in registry entry POI (registry) NCT01280344 (listed in reviews) Phase 2, randomized; n≈320 (registry record) Recovery of gastrointestinal function / GI endpoints (registry) Completed trial per registry but no detailed peer-reviewed results available in retrieved texts Not reported/published in retrieved sources Larger Phase 2 exists but lack of published results creates an evidence gap and potential reporting/publication bias GH secretion (pharmacodynamics) Ishida et al., review (2020) Review summarizing early-phase human PD and preclinical studies; small human PD assessments Pharmacodynamic measures: plasma GH peak timing and magnitude after dosing Ipamorelin produces a rapid GH peak in humans (~0.67 h post-dose) — demonstrating expected PD effect Human safety data limited in review; mainly short-term PD observations Evidence based

wth hormone secretion for anti-aging, recovery, and body composition 💉 Dosing Amount 200-300 mcg per injection Frequency 1-3 times daily (commonly twice daily: morning and before bed) Duration 8-12 weeks, then 2-4 weeks off 💊 Administration Route SC Schedule 1-3 times daily (commonly twice daily: morning and before bed) Timing On empty stomach; morning fasted, post-workout, and/or 30-60 min before bed 📅 Cycle Duration 8-12 weeks, then 2-4 weeks off Rest Period 4 weeks off between cycles Repeatable Yes Preparation & Storage Diluent: Bacteriostatic water ⚗️ Suggested Bloodwork ( 6 tests) IGF-1 When: Baseline Why: Baseline growth hormone activity Fasting glucose and HbA1c When: Baseline Why: GH peptides can affect glucose metabolism CBC with differential When: Baseline Why: Baseline blood cell counts IGF-1 When: 4-6 weeks Why: Confirm GH elevation Fasting glucose When: 4 weeks Why: Monitor glucose handling IGF-1 When: Ongoing Why: Levels above age-adjusted reference range ⚠️ Levels above age-adjusted reference range 💡 Key Considerations → Best taken on empty stomach (2+ hours after eating) → No carbs/fats 30 min before or after injection → Often stacked with CJC-1295 DAC (weekly) or Mod GRF 1-29 (per injection) for synergistic GH release → Contraindication: Avoid in active cancer or pituitary disorders Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — fre

Research shows synergistic GH release when ipamorelin (GHRP) is combined with CJC-1295 no DAC (GHRH analog).

These peptides operate through complementary pathways (GHRH vs GHRP) and are frequently studied in combination for synergistic GH release greater than either alone. → Ipamorelin vs Tesamorelin Tesamorelin is the evidence-backed, FDA-approved choice for HIV-associated lipodystrophy;

Restore access No thanks, continue reading Related Reading Peptide Sermorelin GHRH analog for growth hormone release Peptide CJC-1295 No DAC (Mod GRF 1-29) common stack partner Peptide GHRP-2 growth hormone releasing peptide How Ipamorelin works at the cellular level Overview of Ipamorelin benefits and applications Scientific Details Molecular Formula C38H49N9O5 Molecular Weight 711.85 Da CAS Number 170851-70-4 Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 What is Ipamorelin? # Ipamorelin is a peptide that has been studied in preclinical and clinical research models for its potential therapeutic properties.

Peptide Protocol Wiki June 4, 2026 Retatrutide BPC-157 Tesamorelin + 6 more Guide 12 min read Core Peptides Review 2026: COAs, Finnrick Controversy, and Whether the Score Holds Up An honest 2026 review of Core Peptides covering product range, payment flexibility, shipping, COA transparency, and how the Finnrick Analytics controversy should change how you read vendor ratings.

Peptide Protocol Wiki March 30, 2026 BPC-157 Thymosin Alpha-1 AOD-9604 + 16 more Guide 9 min read Best Growth Hormone Peptides Ranked: 2026 Evidence-Based Guide A ranked comparison of 8 growth hormone secretagogues and related peptides — from FDA-approved tesamorelin to IGF-1 LR3 —

Peptide Protocol Wiki March 30, 2026 BPC-157 Thymosin Alpha-1 AOD-9604 + 16 more Guide 9 min read Best Growth Hormone Peptides Ranked: 2026 Evidence-Based Guide A ranked comparison of 8 growth hormone secretagogues and related peptides — from FDA-approved tesamorelin to IGF-1 LR3 —

Peptide Protocol Wiki March 30, 2026 BPC-157 Thymosin Alpha-1 AOD-9604 + 16 more Guide 9 min read Best Growth Hormone Peptides Ranked: 2026 Evidence-Based Guide A ranked comparison of 8 growth hormone secretagogues and related peptides — from FDA-approved tesamorelin to IGF-1 LR3 —

Can you stack ipamorelin with CJC-1295?

Peptide Protocol Wiki March 14, 2026 Tesamorelin Sermorelin Ipamorelin + 5 more You Might Also Like Related content you may find interesting Peptide Growth Hormone Sermorelin Peptide Growth Hormone GHRP-2 Peptide Growth Hormone GHRP-6 Peptide Growth Hormone Hexarelin Table of Contents What is Ipamorelin?

References # Related Reading # Ipamorelin research studies and evidence Ipamorelin dosing protocols Ipamorelin side effects profile CJC-1295 DAC research guide CJC-1295 without DAC research guide Stay current on Ipamorelin research We summarize new studies, safety updates, and dosing insights — delivered biweekly.